This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
22 citations
,
June 2013 in “Australasian Journal of Dermatology” Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
April 2023 in “Journal of Investigative Dermatology” This study found that olfactory receptor genes are differentially expressed in sweat glands of AIGA patients, suggesting these receptors may play a role in regulating sweating activity.
September 2016 in “Journal of dermatological science” The researchers reported that the OVOL1-OVOL2 axis may play a role in hair follicle differentiation and tumorigenesis, and OVOL1 and OVOL2 are potential diagnostic markers for pilomatricoma and pilomatrix carcinoma.
5 citations
,
October 2022 in “Biology” This study found that CAP1 plays a significant role in reducing ammonium toxicity in Arabidopsis thaliana by promoting shoot growth and maintaining reactive oxygen species homeostasis.
6 citations
,
June 2018 in “PLOS ONE” This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.
1 citations
,
October 2025 in “Frontiers in Immunology” In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.
7 citations
,
January 2019 in “Australasian Journal of Dermatology” In this study, the CYP 21A2 gene p.V281L mutation was associated with an increased susceptibility to familial frontal fibrosing alopecia, suggesting an antigen-driven mechanism linked to certain human leukocyte antigen haplotypes.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Poor air quality increases the risk of atopic dermatitis in Taiwan.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” In this study, researchers developed a novel method combining in silico and in vitro techniques to discover Aromoline, a potential osteoarthritis treatment that increases type II collagen expression in chondrocytes by targeting the dopamine receptor D4.
2 citations
,
December 2020 in “Endocrinology, diabetes & metabolism case reports” This case study highlights the complexity of managing autoimmune polyglandular syndrome type 1, emphasizing the need for thorough clinical history, high suspicion for early diagnosis, and continuous long-term follow-up.
October 2024 in “Journal of the Endocrine Society” This study examined uncharacterized CYP21A2 gene variants related to non-classic congenital adrenal hyperplasia and found that several mutations reduce enzyme activity, which may help improve diagnostic and treatment strategies.
38 citations
,
April 2016 in “The Journal of Pathology” This study found that mice lacking alkaline ceramidase 1 with elevated skin ceramide levels showed disrupted skin homeostasis, including altered hair follicle structures, increased water loss, and a hypermetabolism phenotype.
October 2024 in “Developmental Dynamics” This paper highlights advances in Developmental Dynamics, noting how epoa-deficient zebrafish can model Diamond-Blackfan anemia like disorders for drug screening, Alx4 mouse models offer insights into craniofacial development, and mTORC1 signaling is crucial for retinal development.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.
January 2025 in “Skin Pharmacology and Physiology” This study found that alopecia areata patients have elevated oxidative stress markers, such as OSI and MDA, and reduced antioxidant enzyme activities, suggesting a significant role for oxidative stress in the disease and potential value in targeting it therapeutically.
6 citations
,
January 2024 in “International Journal of Dermatology” This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.
1 citations
,
July 2012 in “Nasza Dermatologia Online” This study found that patients with alopecia areata had significantly higher serum levels of IL-1α compared to healthy controls, with no significant difference observed in IL-1β levels.
6 citations
,
January 2000 in “The Journal of Trace Elements in Experimental Medicine” In this study, an 11-year-old girl with acrodermatitis enteropathica showed significant improvement in symptoms after oral zinc therapy.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.
January 2026 in “Biomedicines” This study identified increased expression of ACAA1 and its regulation by hsa-miR-1343-3p, linking androgenetic alopecia to lipid metabolism pathways, particularly through PPAR signaling, in scalp tissues.
June 2025 in “Turkish Journal of Dermatology” This study found that patients with acne vulgaris had significantly lower serum paraoxonase 1 (PON1) activity compared to healthy controls, suggesting that oxidative stress might play a role in the condition's development.
October 2024 in “Journal of the Endocrine Society” This study found that certain CYP21A2 mutations significantly reduce enzyme activity, contributing to non-classic congenital adrenal hyperplasia phenotypes, which may aid in enhancing diagnosis and treatment strategies.
19 citations
,
August 1972 in “PubMed” This report suggests that a severe reaction involving dermatitis, alopecia, and fever in a patient receiving aurothioglucose was likely allergic, as indicated by clinical findings and a positive lymphocyte transformation test.
This study found that the rs3185480 polymorphism in the APCDD1 gene was associated with an elevated risk of developing androgenic alopecia and reduced protein levels, potentially due to altered codon usage affecting translation efficiency.
This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.
February 2026 in “Journal of Allergy and Clinical Immunology” In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.